Neutralyze Clearing Serum
Salicylic Acid
Kantian Skincare, Llc
Human Otc Drug
NDC 57524-015Neutralyze Clearing Serum also known as Salicylic Acid is a human otc drug labeled by 'Kantian Skincare, Llc'. National Drug Code (NDC) number for Neutralyze Clearing Serum is 57524-015. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Neutralyze Clearing Serum drug includes Salicylic Acid - 20 mg/mL . The currest status of Neutralyze Clearing Serum drug is Active.
Drug Information:
| Drug NDC: | 57524-015 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Neutralyze Clearing Serum |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Salicylic Acid |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Kantian Skincare, Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SALICYLIC ACID - 20 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 15 Jan, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 05 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333D |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Kantian Skincare, LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 346298
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | O414PZ4LPZ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 57524-015-01 | 45 mL in 1 BOTTLE (57524-015-01) | 15 Jan, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose acne treatment
Product Elements:
Neutralyze clearing serum salicylic acid salicylic acid salicylic acid water alcohol dimethicone betaine 1,2-hexanediol mandelic acid ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate copolymer, trimethylolpropane triacrylate crosslinked (45000 mpa.s) dehydroxanthan gum phenoxyethanol ammonia tert-butyl alcohol denatonium benzoate fd&c blue no. 1
Indications and Usage:
Use for the treatment of acne
Warnings:
Warnings for external use only when using this product : skin irritation and dryness are more likely to occur if you use another topical acne medication at the same time. if irritation occurs, only use one topical acne medication at a time unless directed by a doctor. avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. avoid unnecessary sun exposure and use a sunscreen of spf15 or higher. do not use if you have very sensitive skin or are sensitive to salicylic acid. stop use and ask a doctor if irritation becomes severe. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.
Do Not Use:
Warnings for external use only when using this product : skin irritation and dryness are more likely to occur if you use another topical acne medication at the same time. if irritation occurs, only use one topical acne medication at a time unless directed by a doctor. avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. avoid unnecessary sun exposure and use a sunscreen of spf15 or higher. do not use if you have very sensitive skin or are sensitive to salicylic acid. stop use and ask a doctor if irritation becomes severe. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.
When Using:
When using this product : skin irritation and dryness are more likely to occur if you use another topical acne medication at the same time. if irritation occurs, only use one topical acne medication at a time unless directed by a doctor. avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. avoid unnecessary sun exposure and use a sunscreen of spf15 or higher.
Dosage and Administration:
Directions: sensitivity test for a new user: apply product sparingly to one or two small affected areas during the first 3 days. if no discomfort occurs, follow these directions: cover the entire affected area with a thin layer one to three times daily. do not rinse off. because excessive drying or skin irritation may occur, start with one application daily, then gradually increase to two to three times daily if needed or directed by a doctor. if bothersome dryness, peeling or irritation occurs, reduce application to once a day or every other day.
Stop Use:
Stop use and ask a doctor if irritation becomes severe.
Package Label Principal Display Panel:
Principal display panel â bottle label. neutralyze ® neutralyze clearing serum skin repairing acne treatment gel step 2 â repair clears acne, fades dark spots & corrects uneven skin tone controls oil, unclogs & reduces the size of pores 1.52 fl. oz./45 ml principal display panel â bottle label